Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed Nathan Speicher as Chief Financial Officer.
Nate is a seasoned leader with more than 16 years of experience spanning a variety of roles with a particular focus on the biopharmaceutical and pharma services sectors. At BioAgilytix, he is responsible for the strategy, planning and execution of the enterprise’s finance and accounting operations.
Before joining BioAgilytix, he was the Chief Financial Officer for NationsBenefits, a leading supplemental benefits provider serving the managed care space and which was recognized as one of the fastest growing scaled healthcare assets in the U.S.
Previously, Nate served as Chief Commercial Officer for PPD’s laboratory services business (now part of Thermo Fisher Scientific) and held several other roles including Senior Vice President of Finance, where he led the company’s FP&A, Treasury, Capital Markets, and Investor Relations functions. Nate and his team were heavily involved in the company’s 2020 initial public offering. Before PPD, Nathan was the Treasurer for Acelity, a medical device company now part of 3M and earlier in his career served as a Vice President at Morgan Stanley, where he focused on raising capital for clients in the healthcare and biopharmaceutical sectors.
“I am excited to join BioAgilytix at such an exciting time in its trajectory, with key initiatives spanning advanced modalities including cell and gene therapies, expansion into adjacent services and site expansions in the U.S., Europe and Australia underway, all of which will help us better serve our customers as they seek to set a new standard of care for patients,” said Speicher.
“Over the course of my tenure at PPD, I watched BioAgilytix rapidly evolve from a respected but smaller, more specialized lab to that of an organization widely regarded as an industry leader with significant scale and global capabilities. I look forward to further building out our finance team and the positive impact we can have on the Company’s long-term growth.”
Euan Menzies, Chairman and CEO of BioAgilytix, is confident Nathan’s appointment will make a significant contribution to the future success of the company.
He said: “At BioAgilytix, people are our greatest asset. I’m delighted to welcome such a high-caliber leader like Nate to the team, as he will deliver the industry-specific financial expertise needed to propel our growth and best serve our clients.”
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.